News

FDA could make it harder to get young kids a COVID shot

The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy ...

FDA may pull authorization for Pfizer COVID shot for kids under 5

The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy ...

Novavax lifts 2025 revenue outlook after FDA milestone payment

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

Ousted FDA vaccine chief Vinay Prasad is returning to the agency

A Food and Drug Administration official who stepped down less than two weeks ago is getting his job back as the agency's top ...

Novavax higher after Q2 beat as partnerships brighten outlook

Novavax (NVAX) stock gains as the company beats Q2 revenue estimates and raises its 2025 revenue outlook, buoyed by ...

Novavax, Inc. (NASDAQ:NVAX) Q2 2025 Earnings Call Transcript

Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

FDA reinstates ousted top vaccine regulator Vinay Prasad

Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last month, is set to return to his post, according to the Department of Health and Human Services ...
Fierce Pharma1d

FDA may not renew Pfizer's pediatric COVID shot authorization, prompting potential complication for child vaccinations this fall

Shortly after that, the CDC overhauled its vaccine recommendations in COVID, nixing its endorsement of the shots for pregnant women and healthy children. At the time, RFK Jr. said he “couldn’t be more ...

Novavax (NVAX) Profit Jumps on Milestone

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...